Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KZR
KZR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KZR News
Investor Rights Law Firm Investigates Multiple Companies
1d ago
PRnewswire
Investor Rights Law Firm Investigates Multiple Companies
5d ago
PRnewswire
Investor Rights Law Firm Investigates Multiple Companies
Apr 07 2026
PRnewswire
Monteverde Law Firm Investigates Multiple Biotech Companies
Apr 07 2026
Globenewswire
Investigation Launched into Kezar's Transaction with Aurinia
Apr 07 2026
Globenewswire
Investor Rights Law Firm Investigates Multiple Companies
Mar 31 2026
PRnewswire
Ademi LLP Investigates Kezar for Potential Violations
Mar 30 2026
PRnewswire
Aurinia Acquires Kezar Life Sciences for $6.955 per Share
Mar 30 2026
seekingalpha
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences in $6.955 Per Share Deal
Mar 30 2026
NASDAQ.COM
AURINIA PHARMACEUTICALS TO PURCHASE KEZAR LIFE SCIENCES FOR $6.955 PER SHARE IN CASH, ALONG WITH A CONTINGENT VALUE RIGHT
Mar 30 2026
moomoo
Revised: ENODIA THERAPEUTICS - KEZAR TO RECEIVE $1 MILLION UPFRONT AND POTENTIAL MILESTONE PAYMENTS OF UP TO $127 MILLION (CORRECTS OMITTED WORD 'KEZAR')
Mar 12 2026
moomoo
KZR Secures FDA Type C Meeting to Discuss Zetomipzomib Development
Jan 09 2026
NASDAQ.COM
Jefferies Lowers Kezar Life Sciences Rating to Hold and Reduces Price Target to $7
Oct 17 2025
Benzinga
Kezar Initiates Strategic Review Following FDA Setback on Liver Drug Development
Oct 17 2025
Benzinga
Everything You Should Know About the Upgrade to Buy for Kezar Life Sciences (KZR)
Sep 17 2025
NASDAQ.COM
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
Jul 16 2025
Benzinga
Show More News
